1988, ISBN 9780945986003, v, 181
Book
2006, 1, Medical psychiatry, ISBN 0824729447, Volume 33, xviii, 462
Currently, there are a limited amount of guidelines to help clinicians manage patients with obesity and comorbid mental disorders. This expertly written source...
Obesity | complications | Comorbidity | Mental Disorders | therapy | Nutritional aspects | Mental illness | Psychiatry | Endocrinology
Obesity | complications | Comorbidity | Mental Disorders | therapy | Nutritional aspects | Mental illness | Psychiatry | Endocrinology
Book
2007, 1st ed., ISBN 1585622419, xi, 314
Book
The Journal of Clinical Psychiatry, ISSN 0160-6689, 10/2015, Volume 76, Issue 10, pp. e1340 - e1342
Journal Article
The Journal of Clinical Psychiatry, ISSN 0160-6689, 03/2016, Volume 77, Issue 3, pp. e327 - e328
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 12/2019, Volume 28, Issue 12, pp. 1081 - 1094
Introduction: Binge eating disorder (BED) is the most common eating disorder and is frequently associated with psychiatric and medical comorbidities and...
medication | binge eating disorder | pharmacotherapy | Eating disorders
medication | binge eating disorder | pharmacotherapy | Eating disorders
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 01/2016, Volume 77, Issue 1, pp. 90 - 99
Background: Bipolar disorder is among the 10 most disabling medical conditions worldwide While lithium has been used extensively for bipolar disorder since the...
UNITED-STATES | MEDICATION | MAINTENANCE | DEPRESSION | INVENTORY | PSYCHIATRY | DOUBLE-BLIND | MISSING DATA | DIVALPROEX | PLACEBO-CONTROLLED TRIAL | SCALE | PSYCHOLOGY, CLINICAL | Quetiapine Fumarate - adverse effects | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Bipolar Disorder - drug therapy | Quetiapine Fumarate - therapeutic use | Lithium - therapeutic use | Antipsychotic Agents - therapeutic use | Lithium - adverse effects | Adult | Female
UNITED-STATES | MEDICATION | MAINTENANCE | DEPRESSION | INVENTORY | PSYCHIATRY | DOUBLE-BLIND | MISSING DATA | DIVALPROEX | PLACEBO-CONTROLLED TRIAL | SCALE | PSYCHOLOGY, CLINICAL | Quetiapine Fumarate - adverse effects | Antipsychotic Agents - adverse effects | Humans | Middle Aged | Male | Treatment Outcome | Bipolar Disorder - drug therapy | Quetiapine Fumarate - therapeutic use | Lithium - therapeutic use | Antipsychotic Agents - therapeutic use | Lithium - adverse effects | Adult | Female
Journal Article
8.
Full Text
The dual epidemic of tobacco dependence and obesity among those with severe mental illness
Journal of Clinical Psychiatry, ISSN 0160-6689, 03/2016, Volume 77, Issue 3, pp. e327 - e328
SMOKING-CESSATION | PSYCHIATRY | CESSATION WEIGHT-GAIN | CARDIOVASCULAR-DISEASE | RISK | PEOPLE | PSYCHOLOGY, CLINICAL | INTERVENTION | Cardiovascular Diseases - etiology | Cardiovascular Diseases - complications | Humans | Female | Male | Mental Disorders - complications | Weight Gain | Smoking Cessation - methods
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 2009, Volume 70, Issue 3, pp. 12 - 21
Severe mental illness and obesity are each serious public health problems that overlap to a clinically significant extent. Unfortunately, some of the most...
DRUG-NAIVE PATIENTS | PHARMACOLOGICAL-TREATMENT | METABOLIC SYNDROME | NATIONAL EPIDEMIOLOGIC SURVEY | PSYCHIATRY | DOUBLE-BLIND | BODY-MASS INDEX | BIPOLAR-I-DISORDER | INDUCED WEIGHT-GAIN | 1ST-EPISODE SCHIZOPHRENIA-PATIENTS | PLACEBO-CONTROLLED TRIAL | PSYCHOLOGY, CLINICAL | Body Mass Index | Behavior Therapy | Anti-Obesity Agents - administration & dosage | Obesity - drug therapy | Obesity - psychology | Antipsychotic Agents - adverse effects | Humans | Risk Factors | Anti-Obesity Agents - adverse effects | Mental Disorders - complications | Antipsychotic Agents - administration & dosage | Mental Disorders - psychology | Overweight - etiology | Mental Disorders - drug therapy | Obesity - prevention & control | Obesity - therapy | Obesity - etiology | Weight Gain - drug effects | Index Medicus
DRUG-NAIVE PATIENTS | PHARMACOLOGICAL-TREATMENT | METABOLIC SYNDROME | NATIONAL EPIDEMIOLOGIC SURVEY | PSYCHIATRY | DOUBLE-BLIND | BODY-MASS INDEX | BIPOLAR-I-DISORDER | INDUCED WEIGHT-GAIN | 1ST-EPISODE SCHIZOPHRENIA-PATIENTS | PLACEBO-CONTROLLED TRIAL | PSYCHOLOGY, CLINICAL | Body Mass Index | Behavior Therapy | Anti-Obesity Agents - administration & dosage | Obesity - drug therapy | Obesity - psychology | Antipsychotic Agents - adverse effects | Humans | Risk Factors | Anti-Obesity Agents - adverse effects | Mental Disorders - complications | Antipsychotic Agents - administration & dosage | Mental Disorders - psychology | Overweight - etiology | Mental Disorders - drug therapy | Obesity - prevention & control | Obesity - therapy | Obesity - etiology | Weight Gain - drug effects | Index Medicus
Journal Article
Bipolar Disorders, ISSN 1398-5647, 06/2019, Volume 21, Issue 4, pp. 350 - 360
Introduction Depressive episodes are often prevalent among patients with bipolar disorder, but little is known regarding the differential patterns of...
bipolar disorder | depressive symptoms | trajectories | growth mixture modeling | ANTIDEPRESSANT | OUTPATIENTS | ANXIETY | PSYCHIATRY | QUETIAPINE | ADOLESCENCE | NATURAL-HISTORY | NEUROSCIENCES | CLINICAL NEUROLOGY | CHOICE | PREDICTORS | TREATMENT RESPONSE | PRIMARY-CARE PATIENTS | Bipolar disorder | Analysis | Lithium | Patients | Quetiapine
bipolar disorder | depressive symptoms | trajectories | growth mixture modeling | ANTIDEPRESSANT | OUTPATIENTS | ANXIETY | PSYCHIATRY | QUETIAPINE | ADOLESCENCE | NATURAL-HISTORY | NEUROSCIENCES | CLINICAL NEUROLOGY | CHOICE | PREDICTORS | TREATMENT RESPONSE | PRIMARY-CARE PATIENTS | Bipolar disorder | Analysis | Lithium | Patients | Quetiapine
Journal Article
The Journal of Clinical Psychiatry, ISSN 0160-6689, 09/2014, Volume 75, Issue 9, p. e24
Journal Article
The Journal of clinical psychiatry, ISSN 0160-6689, 10/2014, Volume 75, Issue 10, pp. e26 - e26
Patients with bipolar disorder spend more time depressed than manic, but fewer clinical trials have been conducted investigating treatments for bipolar...
Antidepressive Agents, Second-Generation - adverse effects | Isoindoles - administration & dosage | Antipsychotic Agents - adverse effects | Humans | Thiazoles - administration & dosage | Antidepressive Agents, Second-Generation - administration & dosage | Thiazoles - adverse effects | Lurasidone Hydrochloride | Dibenzothiazepines - adverse effects | Isoindoles - pharmacology | Fluoxetine - adverse effects | Fluoxetine - pharmacology | Benzodiazepines - pharmacology | Isoindoles - adverse effects | Dibenzothiazepines - pharmacology | Quetiapine Fumarate | Antidepressive Agents, Second-Generation - pharmacology | Bipolar Disorder - drug therapy | Dibenzothiazepines - administration & dosage | Antipsychotic Agents - administration & dosage | Fluoxetine - administration & dosage | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Thiazoles - pharmacology | Antipsychotic Agents - pharmacology | Drug Combinations
Antidepressive Agents, Second-Generation - adverse effects | Isoindoles - administration & dosage | Antipsychotic Agents - adverse effects | Humans | Thiazoles - administration & dosage | Antidepressive Agents, Second-Generation - administration & dosage | Thiazoles - adverse effects | Lurasidone Hydrochloride | Dibenzothiazepines - adverse effects | Isoindoles - pharmacology | Fluoxetine - adverse effects | Fluoxetine - pharmacology | Benzodiazepines - pharmacology | Isoindoles - adverse effects | Dibenzothiazepines - pharmacology | Quetiapine Fumarate | Antidepressive Agents, Second-Generation - pharmacology | Bipolar Disorder - drug therapy | Dibenzothiazepines - administration & dosage | Antipsychotic Agents - administration & dosage | Fluoxetine - administration & dosage | Benzodiazepines - administration & dosage | Benzodiazepines - adverse effects | Thiazoles - pharmacology | Antipsychotic Agents - pharmacology | Drug Combinations
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 2017, Volume 78, Issue Suppl 1, pp. 14 - 19
Binge-eating disorder (BED) is the most common eating disorder and is associated with poor physical and mental health outcomes. Psychological and behavioral...
OBESITY | LISDEXAMFETAMINE | PSYCHIATRY | COGNITIVE-BEHAVIORAL THERAPY | DOUBLE-BLIND | ADULTS | TOPIRAMATE | PLACEBO-CONTROLLED TRIAL | RANDOMIZED CONTROLLED-TRIAL | ANTIEPILEPTIC DRUGS | PSYCHOLOGY, CLINICAL | ALCOHOL DEPENDENCE | Off-Label Use | Obesity - drug therapy | Obesity - psychology | Humans | Treatment Outcome | Combined Modality Therapy | Binge-Eating Disorder - diagnosis | Psychotropic Drugs - therapeutic use | Randomized Controlled Trials as Topic | Binge-Eating Disorder - psychology | Binge-Eating Disorder - drug therapy | Adult | Cognitive Therapy | Obesity - diagnosis | Lisdexamfetamine Dimesylate - therapeutic use | Patient Education as Topic
OBESITY | LISDEXAMFETAMINE | PSYCHIATRY | COGNITIVE-BEHAVIORAL THERAPY | DOUBLE-BLIND | ADULTS | TOPIRAMATE | PLACEBO-CONTROLLED TRIAL | RANDOMIZED CONTROLLED-TRIAL | ANTIEPILEPTIC DRUGS | PSYCHOLOGY, CLINICAL | ALCOHOL DEPENDENCE | Off-Label Use | Obesity - drug therapy | Obesity - psychology | Humans | Treatment Outcome | Combined Modality Therapy | Binge-Eating Disorder - diagnosis | Psychotropic Drugs - therapeutic use | Randomized Controlled Trials as Topic | Binge-Eating Disorder - psychology | Binge-Eating Disorder - drug therapy | Adult | Cognitive Therapy | Obesity - diagnosis | Lisdexamfetamine Dimesylate - therapeutic use | Patient Education as Topic
Journal Article
The Journal of Clinical Psychiatry, ISSN 0160-6689, 08/2015, Volume 76, Issue 8, pp. e1044 - e1044
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10023, pp. 1085 - 1093
Summary Background Lithium is a first-line treatment in bipolar disorder, but individual response is variable. Previous studies have suggested that lithium...
Internal Medicine | I DISORDER | GADL1 | MEDICINE, GENERAL & INTERNAL | PHARMACOGENETICS | THERAPY | GENOTYPE IMPUTATION | Genome-Wide Association Study | Prospective Studies | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Bipolar Disorder - drug therapy | Bipolar Disorder - genetics | Glial Cell Line-Derived Neurotrophic Factor Receptors - genetics | Genetic Variation | Phenotype | Lithium Compounds - therapeutic use | Polymorphism, Single Nucleotide - genetics | Female | Medical research | Genomics | Medicine, Experimental | Genetic research | Bipolar disorder | Genetic aspects | Transportation equipment industry | Studies | Lithium | Genomes | Gene expression | Drug therapy | Psykiatri | Psychiatry
Internal Medicine | I DISORDER | GADL1 | MEDICINE, GENERAL & INTERNAL | PHARMACOGENETICS | THERAPY | GENOTYPE IMPUTATION | Genome-Wide Association Study | Prospective Studies | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Bipolar Disorder - drug therapy | Bipolar Disorder - genetics | Glial Cell Line-Derived Neurotrophic Factor Receptors - genetics | Genetic Variation | Phenotype | Lithium Compounds - therapeutic use | Polymorphism, Single Nucleotide - genetics | Female | Medical research | Genomics | Medicine, Experimental | Genetic research | Bipolar disorder | Genetic aspects | Transportation equipment industry | Studies | Lithium | Genomes | Gene expression | Drug therapy | Psykiatri | Psychiatry
Journal Article
Clinical and translational science, ISSN 1752-8054, 08/2019
As with other psychiatric disorders, development of drugs to treat binge-eating disorder (BED) has been hampered by high placebo response and dropout rates in...
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 08/2016, Volume 77, Issue 8, pp. 1043 - 1049
Objective: Given that a cohort effect is rarely mentioned as one of the possible contributors to the increased incidence of childhood-onset bipolar disorder in...
UNITED-STATES | MENTAL-HEALTH-SURVEY | LIFETIME PREVALENCE | Bipolar Disorder | METAANALYSIS | MOOD-DISORDERS | AT-ONSET | BIRTH-COHORT | PARENTS | RISK | AGE-OF-ONSET | PSYCHIATRY | PSYCHOLOGY, CLINICAL | United States - epidemiology | Humans | Middle Aged | Netherlands - epidemiology | Male | Germany - epidemiology | Age of Onset | Adult | Family | Female | Registries | Cohort Effect | Bipolar Disorder - epidemiology
UNITED-STATES | MENTAL-HEALTH-SURVEY | LIFETIME PREVALENCE | Bipolar Disorder | METAANALYSIS | MOOD-DISORDERS | AT-ONSET | BIRTH-COHORT | PARENTS | RISK | AGE-OF-ONSET | PSYCHIATRY | PSYCHOLOGY, CLINICAL | United States - epidemiology | Humans | Middle Aged | Netherlands - epidemiology | Male | Germany - epidemiology | Age of Onset | Adult | Family | Female | Registries | Cohort Effect | Bipolar Disorder - epidemiology
Journal Article
Medical Hypotheses, ISSN 0306-9877, 02/2018, Volume 111, pp. 90 - 93
Binge eating, eating an abnormally large amount of food in a discrete period of time with a sense of loss of control over eating, is a defining feature of the...
Journal Article
Journal of Clinical Psychiatry, ISSN 0160-6689, 10/2015, Volume 76, Issue 10, pp. e1340 - e1342
Journal Article
Sexual Medicine Reviews, ISSN 2050-0513, 07/2019, Volume 7, Issue 3, pp. 380 - 392
Introduction: Flibanserin, a multifunctional serotonin agonist and antagonist, is approved by the U.S. Food and Drug Administration (FDA) for treatment of...
Triptans | Antidepressant agents | Drug safety | Flibanserin | Sexual dysfunction
Triptans | Antidepressant agents | Drug safety | Flibanserin | Sexual dysfunction
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.